David Sinclair, a genetics professor at Harvard University, has spent his career researching the aging process and how it can be reversed using epigenetic modifications. Sinclair’s lab recently published a model that explains how aging works and how it can be reversed. By experimenting with mice, Sinclair’s team identified the epigenome as the primary driver of aging, and they successfully rebooted old…
For decades, scientists have been studying the human reproductive system in order to better understand it and develop treatments for various reproductive conditions. Despite this, the ovaries – the organs responsible for producing and releasing eggs in women – have remained surprisingly understudied. Researchers have long sought to create in vitro models of human ovaries, which would allow for more in-depth study…
Biotech company HBM Alpha Therapeutics has raised a seed round to advance its novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), with the lead candidate currently in IND-enabling stage. HBMAT was founded on the expertise of Harbour BioMed’s antibody discovery and development capabilities, and expertise in the molecular pathogenesis and treatment of endocrine disorders of HBMAT’s…
Menopause is defined as the final menstrual period and is typically confirmed after a woman has missed her period for 12 consecutive months. Most women experience menopause between ages 40 and 58. An estimated 45 million women in the U.S. are approaching or in menopause, which results in a decrease in estrogen and other hormones. Hot flashes, vaginal dryness and loss of bone density are…
Male Contraceptive Initiative (MCI), a non-profit, has partnered with the pharmaceutical company Eppin Pharma to provide a Program Related Investment (PRI) of up to $800K to support clinical trial activities for the company’s novel short-term, non-hormonal oral male contraceptive pill. Eppin Pharma’s lead male contraceptive candidate is a small organic compound that binds to EPPIN, a protein on the surface of human…
About a year ago Celmatix, a New York-based pre-clinical stage biotech company focused on ovarian biology, announced, that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec, progressed into hit-identification. Today Celmatix announced that another milestone has been achieved in this alliance, as Evotec and Bayer AG are advancing a second drug program, centered around a novel Celmatix-identified drug target,…
Xosomix, a pre-clinical drug discovery company focused on harnessing diagnostic and therapeutic use of exosomes, the critical communication and transport mediators of the body, announced today the awarding of phase I SBIR grant from Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This grant will enable Xosomix to develop an early diagnostic biomarker for endometriosis. Approximately 10% of…
Gameto, a biotech company using cell engineering to develop therapeutics for diseases of the female reproductive system, has added $17M in funding from Insight Partners, Future Ventures, Arcadia Investment Partners, Bold Capital Partners, Plum Alley, Myelin VC, TA Ventures, Gaingels, Korify Capital, and other existing investors. The new financing brings the total capital raised since inception to $40M. Gameto’s last funding round was announced…
